Investors
OMX Stockholm
( %)
HNSA SEK
Calendar
Upcoming events
06Feb
Full-year Report for January-December 2024
21Mar
Annual Report 2024
17Apr
Interim Report for January-March 2025
Press releases
Our latest press releases
Hansa Biopharma to Attend Jefferies London Healthcare Conference
13/11/2024
Hansa Biopharma to Attend Truist Securities BioPharma Symposium
30/10/2024
Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results
Regulatory press release
17/10/2024
Hansa Biopharma’s HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial
07/10/2024
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
Upcoming
Key progress and look ahead
| Progress to date | What’s next 2H ’24 | Looking ahead - 2025 | |
|---|---|---|---|
| EARLY DEVELEOPMENT | COMPLETED NICE-01 Ph 1safety/tolerability for HNSA-5487 | HNSA-5487 Ph 1 data on exploratory endpoints and clinical development path | HNSA-5487 clinical development |
| TRANSPLANTATION | FULL RANDOMIZATION ConfIdeS Ph 3 trial | 15-HMedIdeS-14 data publication in peer reviewed journal | ConfIdeS Ph 3 12 month follow up and BLA submission in 2H Post Approval Efficacy Study readout |
| GENE THERAPY | STUDY INITIATED: SRP 9001-104 Ph 1 study (DMD) Genethon (Crigler-Najjar) preclinical AskBio (Pompe) preclinical | Genethon trial initiated (Crigler-Najjar) | SRP 9001-104 Ph 1 study (DMD) initial data readout |
| AUTOIMMUNE | TRIAL COMPLETED 15-MedIdeS-09 (GBS) Ph 2 trial 86% ENROLLED GOOD-IDES-12 Ph 3 (anti-GBM) trial | 15-MedIdeS-09 Ph 2 (GBS) data contextualization (IGOS) 16-MedIdeS-12 Ph 2 (AMR) data publication | GOOD-IDES-12 Ph 3 (anti-GBM) 1H full enrolment; 2H data readout |